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Abstract
Alzheimer’s Disease (AD) is the most common neurodegenerative disease 
and the main reason of dementia in the elderly. On the pathological point of 
view, it is characterized by extracellular aggregates of amyloid peptides and 
intracellular deposits of tau protein. These deposits affect neuron viability and 
functions by inducing (among other pathological pathways) oxidative stress 
and triggering mitochondrial dysfunction. It is now evident that free radical-
induced oxidative damage is strongly involved in the pathogenesis of AD. 
Oxidative damage occurs early in disease pathogenesis and can exacerbate 
its progression. Post-mortem brain of individuals affected by AD, evidenced an 
extensive state of oxidative stress compared to healthy controls; markers of 
increased oxidation include, among others, DNA damage. DNA damage can 
induce the activity of the enzyme poly (ADP-ribose) polymerase 1 (PARP-1) 
that catalyze the reaction of poly (ADP-ribosylation). This post-translational 
modification modulates the functions of proteins involved in many physiological 
processes such as gene expression, maintenance of genomic stability and 
cell death. Therefore, inhibiting PARP-1 activity can represent a possible new 
strategy to reduce the impact of the oxidative stress in AD as well as in other 
neurodegenerative diseases. Here we discuss the role of nutrients in modulating 
PARP-1 activity and its perspective potential application.
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macromolecules in cells, including lipids, proteins and nucleic acids 
[4]. DNA damage is a prime activator of the enzyme poly (ADP-
ribose) polymerase 1 (PARP-1) that catalyze the reaction of poly 
(ADP-ribosylation), a post-translational modification of proteins 
involved in many physiological processes such as gene expression, 
maintenance of genomic stability and cell death [5-7]. 
PARP-1 can prompt a spectrum of strategies to induce cell death, 
including the ability of modifying proteins acting as a spatial and 
temporal modulator of a variety of cell signaling pathways such as 
regulation of gene expression, and transcriptional factor such as NF-
kB  activation and protein translocation [8].
Excessive PARP-1 activity has been implicated in the 
pathogenesis of several disorders such as stroke, myocardial 
infarction, inflammation, diabetes, and neurodegenerative disorders 
[9-12]. Therefore, it is not surprising that the search for PARP-1 
inhibitors with specific therapeutic uses (e.g., brain ischemia, cancer) 
has been an active area of research. Beyond medicinal uses, naturally 
occurring PARP-1 inhibitors may also offer a unique preventative 
means at attenuating chronic inflammatory diseases through dietary 
supplementation. This possibility has prompted research for specific, 
naturally occurring inhibitors of PARP-1.
PARP in Alzheimer’s Disease
Love et al. [13] were the first to report a correlation between 
PARP-1 and Alzheimer disease showing by immunostaining assay 
high levels of poly (ADP-ribosylated) proteins in AD human brains. 
So far, other groups have demonstrated PARP-1 activation in AD 
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Introduction
Neurodegenerative diseases are a growing public health concern 
because of the rapid increase in life expectancy in the developed world. 
Indeed, neurodegeneration affects a wide percentage of people and 
are increasing to epidemic proportions in all industrialized countries 
[1]. In particular, the incidence of Alzheimer’s Disease (AD) and 
Parkinson’s Disease (PD) increases with age and the etiology remains 
elusive. There is evidence that oxidative stress, homocysteine related 
vitamins, fats, and alcohol may have a role in the pathogenesis of 
AD. Epidemiological studies suggest that high dietary intake of 
antioxidants, vitamins B6, B12, and folate, unsaturated fatty acids, 
and fish oil are associated to decreased AD risk, although results are 
often contrasting [2,3]. 
Despite the existing evidence does not support the 
recommendation of specific supplements or food, it is clear that 
nutritional approaches able to prevent, delay, slow, or even stop 
the progression of the disease is a promising strategy that deserves 
further and more accurate study. Among the attempted nutritional 
approaches to the treatment of neurodegeneration, several studied 
tried to address the oxidative stress and the antioxidant response 
[2]. As a matter of fact, ROS generation is strictly associated 
with neurodegenerative diseases and causes damage to major 
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using both in vivo and in vitro models: significant PARP-1 activation 
was demonstrated through the evaluation of enzymatic activity and 
western blot in hippocampus and enthorinal cortex of transgenic 
mice TgCRND8 after 3 months, when early amyloid deposit occurs 
[14]. hAPPJ20 mice, which accumulate amyloid beta (Aβ) by the 
age of 6 months, crossed with PARP-1-/- mice, attenuated the brain 
dysfunctions developed, such as microglial activation, hippocampal 
synaptic integrity and cognitive function [15]. Moreover direct 
Aβ injections into hippocampus of mice showed less microglial 
activation induced in the area of injection by Aβ in PARP-1-/- mice or 
treated with the PARP-1 inhibitor PJ34, thus confirming a protective 
role of PARP-1 inhibition.
Rapid accumulation (within 1 hour) of poly(ADP-ribose) 
polymers (PARs) was detected in Aβ-stimulated microglia primary 
cultures [15] and astrocytes [16], indicating enzymatic PARP-1 
activity in non-neuronal cells. In our last work [14] 7PA2 cells (CHO 
cell line stably transfected with a complementary DNA coding for 
APP751 containing the Val717Phe familial Alzheimer’s disease 
mutation that leads to Aβ overproduction) were first assayed for 
PARP-1 activity and a 40% increase was observed in 7PA2 compared 
to control CHO cells. 
The role of PARP-1 has been implicated in the pathogenesis of 
Alzheimer’s disease through several mechanisms. First, as Berger 
suggested 30 years ago [17], excessive PARP-1 activity is related to 
massive NAD depletion that in turns leads to ATP depletion and 
energy failure. This hypothesis has been confirmed over the years 
by other authors, which demonstrated that extracellular NAD+ 
restore neuronal NAD+ levels after PARP-1 activation in astrocytes 
monocultures treated with NMDA [18]. The second mechanism is 
through the regulation of Apoptosis Inducing Factor (AIF) that once 
poly(ADP-ribosylated) by PARP-1 moves to the nucleus and induces 
DNA fragmentation and cell death, called Parthanatos [19-21]. 
Finally, PARP-1 is known to regulate a wide spectrum of function at 
genomic levels, such as chromatin stability or transcriptional activity, 
acting both as a cofactor and as a signaling molecule (Reviewed in 
[22]).
Niacin and PARP
Increasing PARP-1 activity leads to the drastic reduction of NAD+ 
levels, with consequences on the ATP production and impairment of 
cell functions [23]. Thus, extensive PARP-1 activation has been linked 
to the development and progression of various chronic diseases 
including diabetes, cancer, viral infections and neurodegenerative 
diseases [24-27]. 
The activity of PARP-1, as well as DNA synthesis, requires NAD+, 
which derives from Nicotinic acid (NA) and nicotinamide (NAM), 
commonly called niacin.
Nicotinamide, the amide form of NA, is changed to its 
mononucleotide compound with the enzyme nicotinic acid/
nicotinamide adenylyl-transferase, and participates in the cellular 
energy metabolism that directly impacts normal physiology [28]. 
Nicotinamide influences oxidative stress and modulates multiple 
pathways tied to both cellular survival and death [29]. Nicotinamide 
relies upon unique cellular pathways that involve forkhead 
transcription factors, sirtuins, protein kinase B (Akt), Bad, caspases 
[30] and poly (ADP-ribose) polymerase that may offer a fine line with 
determining cellular longevity, cell survival, and unwanted cancer 
progression. 
Niacin is found in variety of foods, including liver, chicken, beef 
meat, fish, cereal, peanuts and legumes; it can be also synthesized 
from  tryptophan, an essential amino acid found in most forms of 
protein. It is well known that insufficient assumption of niacin can be 
responsible for several symptoms including nausea, skin and mouth 
lesions, anemia, headaches and tiredness. Moreover, when niacin 
deficiency becomes chronic, it can cause pellagra [31,32]. Niacin 
and nicotinamide are both precursors of Nicotinamide Adenine 
Dinucleotide  (NAD+) and  nicotinamide adenine dinucleotide 
phosphate  (NADP+); these molecules are coenzymes for many 
dehydrogenases, participating in hydrogen transfer processes. NAD+ 
is important in catabolism of fat, carbohydrates, proteins, and 
alcohol, as well as cell signaling and DNA repair, and NADP mostly in 
anabolism reactions such as fatty acid and cholesterol synthesis. High 
energy requirements (brain) or high turnover rate (gut, skin) organs 
are usually the most susceptible to their deficiency. 
A clear correlation between Niacin deficiency and tissue 
dishomeostasis, mediated by PARP activity has been documented 
in skin. As a matter of fact, keratinocytes maintained under niacin 
deficiency are more sensitive to photodamage, since PARP (and also 
sirtuins) activity is inhibited by low NAD+, with consequent increases 
of DNA damage and cell death [33].
Since in an Oxford University study of older individuals with 
mild cognitive impairment, supplementation with other B-vitamins 
maintained memory performance and reduced the rate of brain 
atrophy [34], supplementation with niacin could be a safe approach 
for a possible clinical trial.
PARP inhibitors
Several drugs designed to inhibit PARP are currently in clinical 
development as anticancer agents due to their capacity to impair DNA 
repair operated by PARP-1 [35]. Anyway, since PARP-1 activation 
leads to NAD and ATP depletion, eventually leading to irreversible 
cellular energy failure, several PARP-1 inhibitors have demonstrated 
a role in counteracting neurodegeneration [14,36]. 
Besides synthetic molecules, several PARP inhibitors are 
endogenous or naturally occurring compounds such as nicotinamide, 
thymidine, or theophylline [37]. Large scale survey using in vitro assay 
system discovered many potent inhibitors [38] and in the last decades 
several new endogenous and naturally occurring regulators of PARP-
1 have been found, which include antibiotics (e.g., tetracyclines), 
vitamins (e.g., vitamin D3) and others [39,40]. The mode of action for 
many of the endogenous and naturally occurring PARP-1 inhibitors 
is unclear, and discrepancies exist in the literature. Among the 
compounds documented as competitive inhibitors with respect to 
NAD+ there are caffeine [41], formycin B [42], NADH and NADP 
[43], nicotinamide [44], taurine [45], theobromine, theophylline and 
thymidine [46]. Some of these molecules are already in use in different 
pathologies, but the vast majority is still studied at preclinical level.
Caloric restriction
Recent findings indicate that Caloric Restriction (CR) may have 
a profound effect on brain function and vulnerability to injury and 
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diseases, by enhancing neuroprotection, stimulating the production 
of new neurons, and increasing synaptic plasticity. CR or energy 
restriction retards age-associated increases in mitochondrial free-
radical production and reduces the accumulation of cell components 
damaged by oxidation. CR has also been shown to slow down age-
related declines in various repair capabilities, including some types of 
DNA repair. It would be of interest to determine if CR can decrease 
the half-life of poly (ADP-ribose) and modulate the activities of PARP 
[47]. It was demonstrated that significant age-associated increase in 
PARP is ameliorated in the frontal cortices of CR rats, suggesting 
that suggest that caloric restriction may provide neuroprotection to 
the aging brain by preserving DNA repair enzymes in their intact 
form, and/or upregulating specific antiapoptotic proteins involved in 
neuronal cell death [48].
Finally, recent studies have also suggested that PARP, as well as 
sirtuins, is a downstream target of CR, which mediate CR-induced 
beneficial effects including life span extension in an NAD(+)-
dependent manner, due to NAD(+) increasing [49].
Conclusion
Increasing evidences indicate that epigenetic mechanisms are 
involved in neurodegenerative disorders onset and progression: 
Although DNA methylation, histone tail modification and micro-
RNAs represent the main, most studied and main neurodegeneration-
associated classes of epigenetic modification, poly(ADP-ribosylation) 
may have a relevant role in neurodegenerative diseases as a 
consequence of the inflammatory and oxidative processes [50]. It is 
not yet completely understood whether PARP activation is totally 
detrimental (in terms of the final pathological phenotype) or if the 
early and low level activation of this class of enzymes rather represent 
a mechanism by which the cell try to cope with the disease. However, 
it is clear that sustained or high level activation is associated to the 
neurodegenerative phenotype in AD and other diseases. Therefore, 
studies aimed at characterizing the effects of PARP inhibition in AD 
models could help to clarify the pathological processes occurring 
in neurodegenerating brain and to disclose the role of PARP and 
its possible use as a therapeutic target. It is also clear that nutrition 
could impact the course of normal versus diseased aging, and that 
nutrients can modulate the epigenome. On these bases, we suggest 
that studying the effects of nutrients possibly regulating PARP 
activity and of natural molecules introduced by diet, showing PARP 
inhibition effect, will be relevant in terms of comprehension AD 
epidemiology and treatment.
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